Supplementary Materialspolymers-10-00752-s001. 1H), 6.59 (s, 1H), 6.80 (dd, = 8.3, 2.1,

Supplementary Materialspolymers-10-00752-s001. 1H), 6.59 (s, 1H), 6.80 (dd, = 8.3, 2.1, 1H), 6.96C7.04 (m, 3H), 7.25 (m, 2H), 7.36 (t, = 7.7, 1H). MS(ESI): 359 (M + Na+). (1b). This monomer was ready from indenol 3b (0.23 g, 0.65 mmol). 1H NMR (400 MHz, CDCl3): 1.06 (t, = 7.1, 3H), 3.82 (s, 3H), 3.87 (s, 3H), 4.11 (q, = 7.1, 2H), 6.33 (s, 1H), 6.59 (s, 1H), 6.82 (dd, = 8.4, 2.4, 1H), 6.93C6.99 (m, 3H), 7.13 (d, = 8.4, 1H), 7.25 (s, 1H), 7.34 (t, = 8.2, 1H). MS(ESI): 359 (M + Na+). (1c). This monomer was prepared from indenol 3c (0.62 g, 1.76 mmol). 1H NMR (400 MHz, CDCl3): 1.12 (t, = 7.1, 3H), Forskolin kinase activity assay 3.86 (s, 3H), 3.87 (s, 3H), 4.15 (q, = 7.1, 2H), 6.30 (s, 1H), 6.55 (s, 1H), 6.83 (dd, = 8.4, 2.3, 1H), 6.97 (d, = 8.8, 2H), 7.16 (d, = 8.4, 1H), 7.25 (d, = 2.4, 1H), 7.37 (d, = 8.8, 2H). MS(ESI): 359 (M + Na+). (1d). This monomer was prepared from indenol 3d (0.32 g, 0.83 mmol). 1H NMR (400 MHz, CDCl3): 1.12 (t, = 7.1, 3H), 3.88 (s, 6H), 3.94 (s, 3H), 4.15 (q, = 7.1, 2H), 6.31 (s, 1H), 6.55 (s, 1H), 6.84 (dd, = 8.4, 2.3, 1H), 6.94C7.02 (m, 3H), 7.17 (d, = 8.4, 1H), 7.24 (s, 1H). MS(ESI): 389 (M + Na+). (1e). This monomer was prepared from indenol 3e (0.43 g, 1.04 mmol). 1H NMR (400 MHz, CDCl3): 1.11 (t, = 7.6, Tgfb3 3H), 3.85 (s, 6H), 3.88 (s, 3H), 3.91 (s, 3H), 4.15 (q, = 7.1, 2H), 6.33 (s, 1H), 6.57 (s, 1H), 6.63 (s, 2H), 6.85 (dd, = 8.4, 2.0, 1H), 7.19 (d, = 8.4, 2H), 7.24 (s, 1H). MS(ESI): 419 (M + Na+). (1f). This monomer was prepared from indenol 3f (0.30 g, 0.81 mmol). 1H NMR (400 MHz, CDCl3): 1.07 (t, = 7.1, 3H), 3.88 (s, 3H), 4.12 (q, = 7.1, 2H), 6.42 (s, 1H), 6.72 (s, 1H), 6.84 (dd, = 8.4, 2.2, 1H), 6.98 (d, = 8.4, 1H), 7.28 (d, = 2.2, 1H), 7.56 (d, = 8.8, 2H), 8.31 (d, = 8.8, 2H). MS(ESI, unfavorable ions): 701 (2M ? H+). (1g). Forskolin kinase activity assay This monomer was prepared from indenol 3g (0.22 g, 0.54 mmol). 1H NMR (400 MHz, CDCl3): 1.09 (t, = 7.1, 3H), 3.87 (s, 3H), 4.13 (q, = 7.1, 2H), 6.35 (s, 1H), 6.63 (s, 1H), 6.83 (dd, = 8.4, 2.3, 1H), 7.06 (d, = 8.4, 1H), 7.25 (d, = 2.4, 1H), 7.27 (d, = 8.4, 2H), 7.57 (d, = 8.4, 2H). MS(ESI): 407, 409 (M + Na+). (1h). This Forskolin kinase activity assay monomer was prepared from indenol 3h (0.25 g, 0.80 mmol) and 1 equivalent of PTSA. 1H NMR (400 MHz, CDCl3): 1.30 (t, = 7.2, 3H), 3.88 (s, 3H), 4.28 (q, = 7.1, 2H), 6.29 (s, 1H), 6.49 (s, 1H), 6.68 (s, 1H), 6.87 (dd, = 8.4, 2.3, 1H), 7.24 (d, = 2.2, 1H), 7.36 (d, = 8.4, 1H), 7.52 (s, 1H) 7.84 (s, 1H). MS (ESI): 319 (M + Na+). 2.1.2. General Procedure for the Preparation of Polybenzofulvene Derivatives Poly-1bCe,g,h by Spontaneous Polymerization. A stock solution of suitable monomer (1bCe,g,h) in chloroform (about 0.05 M) was concentrated under reduced pressure to give a viscous oil, which was dissolved into chloroform (20 mL/mmol of monomer) and newly evaporated. Forskolin kinase activity assay The dissolution/evaporation procedure was repeated from three to nine times, monitoring by TLC the progressive disappearance of the monomer in solution. The final residue was washed with the indicated solvent or dissolved into a small amount of CHCl3 and precipitated in the reported bad solvent to give the expected polymer. (Poly-1b). This polymer was obtained from a Forskolin kinase activity assay stock solution of benzofulvene.